Medizinische Universität Graz Austria - Forschungsportal - Medical University of Graz

Navigation/Suche

Abstract: Pulmonary hypertension (PH) describes a group of devastating diseases, comprising idiopathic and secondary forms, which cause breathlessness and premature death, representing a major burden on healthcare systems. Extensive lung vascular remodelling with loss of vessel patency is the underlying pathomechanism in PH. PULMOTENSION integrates the top EU Centres in PH and lung vascular biology in a multidisciplinary approach, with the aim to combat and finally cure PH. The expertise of all members fully extends from the initially discovery of gene mutations causative of PH to having established new therapeutic regimen of PH. We will uncover underlying molecular pathways, identify distinct targets for anti-remodelling therapy, foster drug development based on these targets, and test these new treatment options in preclinical and clinical trials.
Gender issues will be particularly addressed, as many PH forms have a female preponderance. Hence, this ambitious translational research programme will span "from molecules to patients" to the benefit of molecular understanding and new treatments of PH, a prototype disease of vascular remodelling.

Projektpartner: Alphalyse, Dänemark.; Altanapharma, Deutschland.; BioSpring GmbH, Deutschland.; Bologna Pulmonary Hypertension Centre, Bologna, Italien.; Charite-Universitätsmedizin Berlin, Berlin, Deutschland.; Dr. Riethmüller MRS GmbH, Deutschland.; Dualsystems GmbH, Schweiz.; Genolyze Ltd., Finnland.; Hannover Medical School, Hannover, Deutschland.; Hopital Antoine Beclere, Université Paris Sud, Frankreich.; Hospital Clinic i provincial de Barcelona, Barcelona, Spanien.; Imperial College London, London, Großbritannien.; INSERM, Frankreich.; King's College London, London, Großbritannien.; LEA Medizintechnik GmbH, Deutschland.; Luxcel Biosciences Ltd., Irland.; Medizinische Universität Wien (MUW), Spitalgasse 23, 1090 Wien, Österreich.; Scottish Pulmonary Vascular Unit, Großbritannien.; TransMIT GmbH, Deutschland.; Universität Duisburg - Essen, Essen, Deutschland.; Universität Giessen, Giessen, Deutschland.
Kontaktperson: Prof. Dr. Stefan Hormuth, Prof. Dr. Werner Seeger;; Universitätsklinikum Heidelberg, Heidelberg, Deutschland.; Université Libre de Bruxelles, Brüssel, Belgien.; University College, London, London, Großbritannien.; University of Cambridge, Cambridge, Großbritannien.; University of Glasgow, Glasgow, Großbritannien.; University of Ioannina, Griechenland.; University of Oxford, Oxford, Großbritannien.; University of Sevilla, Sevilla, Spanien.; University of Zurich, Zürich, Schweiz.

Gefördert durch: Europäische Kommission, Rue de la Loi, Brussels, Europäische Union